BRIEF published on 12/11/2025 at 07:05, 10 days ago BioVersys lance un essai de phase 3 pour le BV100 et fait le point sur ses progrès commerciaux. Introduction En Bourse BioVersys Résistance Aux Médicaments BV100 Phase 3 Recherche Antibactérienne
BRIEF published on 12/11/2025 at 07:05, 10 days ago BioVersys Initiates Phase 3 Trial for BV100 and Updates Business Progress IPO Drug Resistance BioVersys BV100 Phase 3 Antibacterial Research
PRESS RELEASE published on 12/11/2025 at 07:00, 10 days ago BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update BioVersys AG initiates BV100 Phase 3 study for ventilator-associated bacterial pneumonia, achieving significant milestones in 2025 and upcoming key events in 2026 Clinical Trials Biopharmaceutical BioVersys AG BV100 Phase 3 Ventilator Associated Bacterial Pneumonia
BRIEF published on 11/10/2025 at 07:05, 1 month 11 days ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
BRIEF published on 11/10/2025 at 07:05, 1 month 11 days ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
PRESS RELEASE published on 11/10/2025 at 07:00, 1 month 11 days ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 1 month 15 days ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 1 month 15 days ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 1 month 15 days ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF published on 11/05/2025 at 07:05, 1 month 16 days ago BioVersys to Present at Stifel 2025 Annual Healthcare Conference New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
Published on 12/20/2025 at 00:30, 1 day 6 hours ago Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 1 day 9 hours ago GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 1 day 12 hours ago Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 1 day 16 hours ago Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 1 day 17 hours ago Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF
Published on 12/20/2025 at 16:45, 14 hours 26 minutes ago Shanghai Electric Powers Up Iraq's Energy Future with Major 625MW Efficiency Upgrade
Published on 12/20/2025 at 10:05, 21 hours 6 minutes ago FITUR 2026 highlights the strong synergies between Germany and Spain
Published on 12/19/2025 at 22:03, 1 day 9 hours ago EAMD: Trading resumes on the Düsseldorf Stock Exchange, lawsuit filed by minority shareholders dismissed, capital increase for investments in drone projects in the defense tech sector
Published on 12/19/2025 at 21:40, 1 day 9 hours ago IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries
Published on 12/19/2025 at 20:35, 1 day 10 hours ago Nobu Manchester breaks ground as Robert De Niro visits Manchester with Salboy
Published on 12/19/2025 at 21:57, 1 day 9 hours ago Mise à disposition du document d’enregistrement universel
Published on 12/19/2025 at 08:30, 1 day 22 hours ago Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 1 day 22 hours ago Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 2 days ago EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 2 days ago EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
